Deep-pocketed investors have adopted a bearish approach towards Moderna MRNA, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MRNA usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Moderna. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 20% leaning bullish and 80% bearish. Among these notable options, 7 are puts, totaling $805,450, and 3 are calls, amounting to $373,125.
Expected Price Movements
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $65.0 to $130.0 for Moderna during the past quarter.
Volume & Open Interest Development
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Moderna's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Moderna's whale trades within a strike price range from $65.0 to $130.0 in the last 30 days.
Moderna 30-Day Option Volume & Interest Snapshot
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| MRNA | PUT | TRADE | BEARISH | 07/19/24 | $65.00 | $608.0K | 278 | 0 |
| MRNA | CALL | TRADE | BULLISH | 01/19/24 | $75.00 | $189.9K | 3.4K | 14 |
| MRNA | CALL | TRADE | BEARISH | 12/15/23 | $75.00 | $122.4K | 2.6K | 59 |
| MRNA | CALL | TRADE | BEARISH | 12/15/23 | $65.00 | $60.7K | 134 | 52 |
| MRNA | PUT | SWEEP | BEARISH | 12/15/23 | $75.00 | $42.0K | 1.4K | 1 |
About Moderna
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Moderna's Current Market Status
- Trading volume stands at 1,164,808, with MRNA's price down by -0.4%, positioned at $76.24.
- RSI indicators show the stock to be is currently neutral between overbought and oversold.
- Earnings announcement expected in 97 days.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Moderna options trades with real-time alerts from Benzinga Pro.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date of Trade | ticker | Put/Call | Strike Price | DTE | Sentiment |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
